Tags

Type your tag names separated by a space and hit enter

Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts.
Anticancer Res. 2007 Mar-Apr; 27(2):719-27.AR

Abstract

Based on our studies demonstrating first time evidence that the cyclooxygenase-2 (Cox-2) enzyme is abundant within invasive human breast tumors, we developed a clonally derived human breast tumor cell clone designated as MCF-7/Cox-2 Clone 10 by transfection of human Cox-2 cDNA into slow growing, Cox-2 null, non-metastatic MCF-7 human breast tumor cells. The present studies evaluated the biological characteristics of the MCF-7/Cox-2 Clone 10 human breast tumors compared to the characteristics of MCF-7/empty vector control tumors when grown in vivo following injection of 5x10(6) tumor cells into mammary fat pads of ovariectomized female Crl:Nu-Foxn1(nu) mice implanted with slow release 17-beta estradiol pellets. At 60 days after tumor cell injection, MCF-7/Cox-2 Clone 10 human breast tumors were 4-fold greater (p < 0.01) in volume than MCF-7/empty vector control tumors. MCF-7/Cox-2 Clone 10 human breast tumor xenografts were highly angiogenic based on histological observation of large-bore blood vessels, which was confirmed by immunohistochemical staining with anti-CD-31 antibody and quantitation of mean vessel density. MCF-7/Cox-2 Clone 10 human breast tumor cells were present within regional lymph nodes adjacent to mammary fat pads with their local invasion confirmed by Western blotting of Cox-2-protein. This unique Cox-2-dependent breast tumor model rapidly produces large, angiogenic, locally invasive human breast tumor xenografts in mammary fat pads of ovariectomized female Crl:Nu-Foxn1(nu) mice at 42-60 days which recapitulate human breast ductal carcinomas. This unique model may be invaluable as a means to evaluate preclinical safety and efficacy of novel adjuvant therapies for women with metastastic breast cancer including prostanoid receptor antagonists, newly developed anti-angiogenic therapies, as well as other novel approaches for targeting and destruction of human breast tumors and their vasculature.

Authors+Show Affiliations

Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. frobertson@mdanderson.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

17465194

Citation

Robertson, Fredika M., et al. "Cyclooxygenase-2 Directly Induces MCF-7 Breast Tumor Cells to Develop Into Exponentially Growing, Highly Angiogenic and Regionally Invasive Human Ductal Carcinoma Xenografts." Anticancer Research, vol. 27, no. 2, 2007, pp. 719-27.
Robertson FM, Mallery SR, Bergdall-Costell VK, et al. Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts. Anticancer Res. 2007;27(2):719-27.
Robertson, F. M., Mallery, S. R., Bergdall-Costell, V. K., Cheng, M., Pei, P., Prosperi, J. R., & Ferrari, M. (2007). Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts. Anticancer Research, 27(2), 719-27.
Robertson FM, et al. Cyclooxygenase-2 Directly Induces MCF-7 Breast Tumor Cells to Develop Into Exponentially Growing, Highly Angiogenic and Regionally Invasive Human Ductal Carcinoma Xenografts. Anticancer Res. 2007 Mar-Apr;27(2):719-27. PubMed PMID: 17465194.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts. AU - Robertson,Fredika M, AU - Mallery,Susan R, AU - Bergdall-Costell,Valerie K, AU - Cheng,Mark, AU - Pei,Ping, AU - Prosperi,Jenifer R, AU - Ferrari,Mauro, PY - 2007/5/1/pubmed PY - 2007/5/11/medline PY - 2007/5/1/entrez SP - 719 EP - 27 JF - Anticancer research JO - Anticancer Res VL - 27 IS - 2 N2 - Based on our studies demonstrating first time evidence that the cyclooxygenase-2 (Cox-2) enzyme is abundant within invasive human breast tumors, we developed a clonally derived human breast tumor cell clone designated as MCF-7/Cox-2 Clone 10 by transfection of human Cox-2 cDNA into slow growing, Cox-2 null, non-metastatic MCF-7 human breast tumor cells. The present studies evaluated the biological characteristics of the MCF-7/Cox-2 Clone 10 human breast tumors compared to the characteristics of MCF-7/empty vector control tumors when grown in vivo following injection of 5x10(6) tumor cells into mammary fat pads of ovariectomized female Crl:Nu-Foxn1(nu) mice implanted with slow release 17-beta estradiol pellets. At 60 days after tumor cell injection, MCF-7/Cox-2 Clone 10 human breast tumors were 4-fold greater (p < 0.01) in volume than MCF-7/empty vector control tumors. MCF-7/Cox-2 Clone 10 human breast tumor xenografts were highly angiogenic based on histological observation of large-bore blood vessels, which was confirmed by immunohistochemical staining with anti-CD-31 antibody and quantitation of mean vessel density. MCF-7/Cox-2 Clone 10 human breast tumor cells were present within regional lymph nodes adjacent to mammary fat pads with their local invasion confirmed by Western blotting of Cox-2-protein. This unique Cox-2-dependent breast tumor model rapidly produces large, angiogenic, locally invasive human breast tumor xenografts in mammary fat pads of ovariectomized female Crl:Nu-Foxn1(nu) mice at 42-60 days which recapitulate human breast ductal carcinomas. This unique model may be invaluable as a means to evaluate preclinical safety and efficacy of novel adjuvant therapies for women with metastastic breast cancer including prostanoid receptor antagonists, newly developed anti-angiogenic therapies, as well as other novel approaches for targeting and destruction of human breast tumors and their vasculature. SN - 0250-7005 UR - https://www.unboundmedicine.com/medline/citation/17465194/Cyclooxygenase_2_directly_induces_MCF_7_breast_tumor_cells_to_develop_into_exponentially_growing_highly_angiogenic_and_regionally_invasive_human_ductal_carcinoma_xenografts_ L2 - http://ar.iiarjournals.org/cgi/pmidlookup?view=long&amp;pmid=17465194 DB - PRIME DP - Unbound Medicine ER -